Chemical Biology & Drug Design · 2008 · 51 citations · 41 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsBacterial ToxinsEnzyme InhibitionMolecular Mechanisms Of ToxicityStructure-activity Relationship AnalysisToxin-mediated PathogenesisBotulinum NeurotoxinBotulinum ToxinsDrug Candidate OptimizationIn Vivo Efficacy TestingIn Vivo StudiesToxin BiochemistryToxin FunctionToxin Structure
In this study, we analyzed a series of rhodanine derivatives, as potential inhibitors of bacterial toxins, namely the proteases anthrax lethal factor and the botulinum neurotoxin type A. Conducting an extensive structure-activity relationship study on rhodanine derivatives, we profiled their selectivity against the two bacterial toxins and two related human metalloproteases using in vitro assays. In addition, we examined initial in vitro ADME-Tox properties of selected compounds and their ability to protect lethal factor-induced cell death of macrophages. These data allowed the selection of one additional drug candidate for which preliminary in vivo efficacy studies against anthrax spores were conducted. Integration of these results with our structure-activity relationship studies provides a framework for the development of potential drug candidates against anthrax and botulinum.
41
Matthew Eldridge, Christopher W. Murray, T.R. Auton et al. · Journal of Computer-Aided Molecular Design · 1997 · 1.7K citations
Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor
Nicholas S. Duesbery, Craig P. Webb, Stephen H. Leppla et al. · Science · 1998 · 1K citations